表紙
市場調査レポート

希少疾患用医薬品の世界市場の将来展望

Global Orphan Drugs Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 349903
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
希少疾患用医薬品の世界市場の将来展望 Global Orphan Drugs Market Outlook 2020
出版日: 2016年01月01日 ページ情報: 英文 64 Pages
概要

希少疾患用医薬品 (希用薬) は別名「ニッチ・バスター」とも呼ばれ、まだ満足な治療法が見つかっていない希少疾患の患者を治療するために開発・製造されたものです。治療法がまだ無い希少疾患の患者は全世界で4000〜5000人にすぎませんが、ブロックバスター薬の特許満了やジェネリック医薬品との競合を受けて、製薬業界では希少疾患治療薬の開発に乗り出しつつあります。各国政府からの支援もまた、市場成長の一因となっています。希少疾患用医薬品の世界市場は、2020年には1億8000万米ドルの規模に達する見通しです。

当レポートでは、世界の希少疾患用医薬品 (オーファンドラッグ) の市場について分析し、市場の全体的構造や促進・抑制要因、市場全体および種類別・地域別・用途別の動向見通し、治験中のパイプライン製品の情報、今後の製品開発・市場成長の方向性、主要企業のプロファイルと製品概要などについて調査しております。

第1章 アナリストの見解

第2章 分析手法

第3章 希少疾患用医薬品:概要

第4章 市場の促進要因と課題

  • 市場促進要因
    • 医療費支出の増大
    • 慢性疾患の有病者数の増加
    • 開発期間の短縮とODE (希少疾患用医薬品の独占権)
    • 補助金・税額控除
  • 課題
    • 希少疾患用医薬品のコストの高さ
    • 病歴に対する認識や治験参加者の不足
    • ジェネリック医薬品業界との競争激化

第5章 世界の希少疾患用医薬品市場:概要

第6章 市場の内訳

  • 種類別
  • 地域別
  • 用途別

第7章 希少疾患用医薬品のパイプライン製品の現状

第8章 市場の傾向と発展

  • 腫瘍向け希少疾患用医薬品の件数増加
  • 遺伝子療法:希少疾患の治療法としての人気の拡大

第9章 企業合併・買収 (M&A)

第10章 規制シナリオ

  • 米国
  • 欧州
  • 日本
  • インド
  • 中国

第11章 競争環境

第12章 主要企業の分析

  • Novartis
  • F. Hoffmann-La Roche AG
  • Celgene Corporation
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmbH
  • AbbVie

第13章 機会と提言

  • 市場機会
  • 提言

図表一覧

目次

Orphan drugs, also called niche busters, are intended to treat patients suffering from very serious diseases for which no treatment or at least a satisfactory one, has so far been available. These diseases, often referred to as orphan diseases or rare diseases, affect only a small portion of the population. The number of diseases for which no treatment is currently available is estimated to be between 4,000 to 5,000, worldwide. The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of pharmaceutical industry from the essential medicines to orphan drugs. Incentives for drug development provided by governments, as well as support from the regulatory bodies, are a further boost for the companies developing orphan drugs all over the world.

According to the report “Global Orphan Drugs Market Outlook 2020”, the orphan drug market is anticipated to reach around US$ 180 Billion by 2020. The report provides a detailed analysis of the market for these orphan drugs. An estimation of the market potential of these drugs has been done keeping in mind that many more of these drugs are being tested in clinical trials for various indications, apart from the ones that are already approved. Furthermore, the report also provides the revenue generated by top 10 orphan drugs in 2014.

The report provides information about the segments of the orphan drug market on the basis of type, geography, and therapeutic application. It also highlights orphan drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth. The regulatory scenario of orphan drug industry across different geographic regions of the world has also been discussed in the report.

The later part of the report discusses some of the prominent players in the global orphan drug market. A brief business overview of each player has been provided along with their business segments, product portfolios, and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Orphan Drug - An Introduction

4. Drivers and Challenges

  • 4.1. Drivers
    • 4.1.1. Rising Healthcare Expenditure
    • 4.1.2. Increasing Prevalence of Chronic Diseases
    • 4.1.3. Shorter Development Timeline & Orphan Drug Exclusivity (ODE)
    • 4.1.4. Grants and Tax Credits
  • 4.2. Challenges
    • 4.2.1. High Cost of Orphan Drugs
    • 4.2.2. Lack of Disease History Awareness & Research Participants
    • 4.2.3. Increased Competition from Generics Industry

5. Global Orphan Drug Market - Overview

6. Market Segmentation

  • 6.1. By Type
  • 6.2. By Geography
  • 6.3. By Applications

7. Current Status of Orphan Drugs in Pipeline

8. Trends and Developments

  • 8.1. Rise in Number of Orphan Drugs for Oncology
  • 8.2. Gene Therapy- Gaining Popularity for Rare Conditions

9. Mergers and Acquisitions

10. Regulatory Scenario

  • 10.1. US
  • 10.2. EU
  • 10.3. Japan
  • 10.4. India
  • 10.5. China

11. Competitive Landscape

12. Key Player Analysis

  • 12.1. Novartis
  • 12.2. F. Hoffmann-La Roche AG
  • 12.3. Celgene Corporation
  • 12.4. Pfizer Inc.
  • 12.5. Sanofi
  • 12.6. Bristol-Myers Squibb
  • 12.7. Johnson & Johnson
  • 12.8. Merck & Co., Inc.
  • 12.9. Boehringer Ingelheim GmbH
  • 12.10. AbbVie

13. Opportunities & Recommendations

  • 13.1. Opportunities
  • 13.2. Recommendations

List of Figures:

  • Figure 5-1: Global - Orphan Drugs Market (Billion US$), 2014-2020
  • Figure 6-1: Global - Orphan Drugs Market by Type (%), 2014
  • Figure 6-2: Global - Orphan Drugs Market by Geography (%), 2014
  • Figure 6-3: Global - Orphan Drugs Market by Applications (%), 2014
  • Figure 11-1: Share of Major Players in Orphan Drugs Market (%), 2014
  • Figure 12-1: Novartis - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-2: Roche - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-3: Celgene Corporation - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-4: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-5: Sanofi - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-6: Bristol Myers Squibb - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-7: Johnson & Johnson - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-8: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-9: Boehringer Ingelheim GmbH - Break up of Revenue by Geographies (%), 2014
  • Figure 12-10: AbbVie - Break up of Revenue by Geographies (%), 2014

List of Tables:

  • Table 7-1: Major Orphan Drugs Pipeline
  • Table 9-1: Major Consolidations in Orphan Drug Market (2014-2015)
  • Table 11-1: Global - Major Orphan Drugs Revenue (Billion US$), 2014
  • Table 12-1: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-2: Novartis - Orphan Drugs
  • Table 12-3: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-4: Roche - Orphan Drugs
  • Table 12-5: Celgene Corporation - Orphan Drugs
  • Table 12-6: Pfizer Inc - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 12-7: Pfizer Inc - Orphan Drugs
  • Table 12-8: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-9: Sanofi - Orphan Drugs
  • Table 12-10: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-11: Bristol Myers Squibb - Orphan Drugs
  • Table 12-12: Johnson & Johnson - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-13: Johnson & Johnson - Orphan Drugs
  • Table 12-14: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-15: Merck & Co., Inc. - Orphan Drugs
  • Table 12-16: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 12-17: Boehringer Ingelheim GmbH - Orphan Drugs
  • Table 12-18: AbbVie - Orphan Drugs
Back to Top